Other CDK4/6 inhibitor-based regimens have also demonstrated efficacy in elderly patients [23, 27], further supporting CDK4/6 inhibitors as a valuable treatment option in elderly patients with HR+ advanced breast cancer. Here, CDK4 is linked to breast carcinoma.